Results 161 to 170 of about 271,655 (296)

Primary Pulmonary Hodgkin Lymphoma: A Cytologic Diagnostic Challenge. [PDF]

Diagn Cytopathol
Tan NJH, Torous VF.
europepmc   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

A Rare Case of Motor Neuropathy Secondary to Non-Hodgkin Lymphoma. [PDF]

Cureus
Correa Lopez D, Estrada M, Uribe González R, Cardona R, Velez C.   +4 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma. [PDF]

Cancer
Tharmaseelan H, Jablonski J, Bühnen I, Fuchs M, Rosenbrock J, Eich HT, Ferdinandus J, Jaworek CP, Bröckelmann PJ, Borchmann P, Eichenauer DA.   +10 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab. [PDF]

Mediterr J Hematol Infect Dis
Salvatore F, Casadei B, Mazzoni C, Gentilini M, Argnani L, Zinzani PL.   +5 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Mortality in Patients With Hodgkin Lymphoma and Heart Failure: A Swedish Population-Based Study. [PDF]

JACC Adv
Godtfredsen SJ, Eloranta S, Smedby KE, Antonilli S, Baech J, Molin D, Kragholm K, El-Galaly TC, Dietrich CE.   +8 more
europepmc   +1 more source